Abstract:  Objective  To analyze the association of mutation and clinicopathological features according epidermal growth factor receptor （EGFR） mutation subtype in nonsmall cell lung cancer （NSCLC）. Methods  From January 2015 to December 2017， a total of 203 pathological samples were enrolled， including paraffin section 113 cases， fresh resected tissue 41 cases and pleural effusion 49 cases. Their EGFR mutation was detected with ARMS-Taqman. The relationships between EGFR and clinicopathological features were analyzed. Logistic regression model was used to analyze the factors influencing EGFR mutation. Results  Among these samples， 97 had EGFR mutation （47.8％）， with 82 were of TKIs sensitive mutation（including 44 L858R mutation, 35 19-del mutation, 1 G719C/G719S mutation and 2 L861Q/S768I mutation）， 7 were of TKIs resistant mutation， and 8 were of multi-location mutation. Multi-location mutation was almost T790M mutation （87.5%）， mainly in male, stage Ⅳ and and adenocarcinoma patients. EGFR mutations occurred more frequently in female， non-smokers and adenocarcinoma patients. 19-del and L858R mutations occurred predominantly in female， accounting for 57.1％ and 54.5％，respectively. Other mutation types occurred predominantly in male （72.2％）. EGFR mutation rate was higher in patients without smoking history with binary Logistic regression analysis（HR=4.146，95%CI：1.802-9.536）. Conclusion  The EGFR gene mutation in NSCLC patients in Sichuan province were mainly found in L858R and 19-del. EGFR mutation was more frequently occurred in female， non-smoker and lung adenocarcinoma patients. Smoking status was independent predictors of EGFR mutation.

Key words: font-family:宋体, Non-small cell lung cancer">Non-small cell lung cancerfont-family:宋体, （NSCLC）')">">（NSCLC）, Gene typing, DNA mutation analysis, Epidermal growth factor receptor（EGFR）